Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer
Purpose To evaluate adherence to abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Methods In an observational prospective cohort study, we monitored patients with mCRPC for their adherence to abiraterone or enzalutamide in the pre- or post-che...
Gespeichert in:
| Veröffentlicht in: | Supportive care in cancer 2020-10, Vol.28 (10), p.4687-4695 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4695 |
|---|---|
| container_issue | 10 |
| container_start_page | 4687 |
| container_title | Supportive care in cancer |
| container_volume | 28 |
| creator | Banna, Giuseppe L. Urzia, Valeria Benanti, Chiara Pitrè, Alessandra Lipari, Helga Di Quattro, Rosario De Giorgi, Ugo Schepisi, Giuseppe Basso, Umberto Bimbatti, Davide Rundo, Francesco Libra, Massimo Malatino, Lorenzo |
| description | Purpose
To evaluate adherence to abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Methods
In an observational prospective cohort study, we monitored patients with mCRPC for their adherence to abiraterone or enzalutamide in the pre- or post-chemotherapy setting.
Results
Fifty-eight patients with median age of 76 years (range 56–94), age-adjusted Charlson comorbidity score of 10 (range, 4–15), and geriatric G8 score of 14 (range, 6–17) were enrolled. Twenty-two (38%) patients were treated with abiraterone and 36 (62%) with enzalutamide, while forty-two (72%) were in the pre-chemotherapy setting. Forty-seven patients (81%) had a caregiver. Based on the pill counting, a non-adherence rate of 4.8% and 6.2% was observed for the whole period and the first 3 months, respectively, without a statistically significant difference between abiraterone and enzalutamide cohorts. A lower non-adherence rate (1.3%) was reported by patients during the whole period, mainly due to a misperception (77%) and forgetfulness (19%). Non-adherence rate to the fulfilling of the clinical diary was 38% for the whole period. Non-adherence in the whole period was related to the radiological response (
p
= 0.03) and geriatric G8 score (
p
= 0.005). By the receiver operating characteristic (ROC) curve based on the radiological response, non-adherence cut-off was 1.87% (
p
= 0.04). By this non-adherence cut-off, the G8 cut-off was 14.75 (
p
= 0.0003).
Conclusion
Non-adherence to abiraterone or enzalutamide for mCRPC may have an impact on disease response and be related to patients’ frailty, suggesting their geriatric assessment and clinical interventions to monitor and increase their adherence. |
| doi_str_mv | 10.1007/s00520-020-05311-5 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2343051088</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A633569545</galeid><sourcerecordid>A633569545</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-d73748c89128aba7d7b8f0add7f97a4936d2f90e5fe83e4db72acd5c8927a0313</originalsourceid><addsrcrecordid>eNp9Uc9vFiEQJUZjP6v_gAdD4sXLVmBgWY5fGn8lTbzombAwW2l22Qrsof71svmqjcYYMoHMvPeYmUfIS84uOGP6bWFMCdaxPRRw3qlH5MAlQKcBzGNyYEbyToJSZ-RZKTeMca2VeErOgJuecSEPxB_DN8yYPNK6UjfG7CrmNSFdM8X0w81bdUsMSGOiOAfM8x1dsLpSXY2e-vZolLimLmOJLZsqvc3rXsZWbcL5OXkyubngi_v7nHx9_-7L5cfu6vOHT5fHq85LKWoXNGg5-MFwMbjR6aDHYWIuBD0Z7aSBPojJMFQTDoAyjFo4H1QjCO0YcDgnb0667f_vG5Zql1g8zrNLuG7FCpDAFGfD0KCv_4LerFtOrTsrJPRG94qrB9S1m9HGNK1tVr-L2mMPoHqj5I66-AeqnYBL9G2VU2z5PwjiRPBtTyXjZG9zXFy-s5zZ3Vl7ctayPXZn7U56dd_xNi4YflN-WdkAcAKUVkrXmB9G-o_sT9oArd4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2436976515</pqid></control><display><type>article</type><title>Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Banna, Giuseppe L. ; Urzia, Valeria ; Benanti, Chiara ; Pitrè, Alessandra ; Lipari, Helga ; Di Quattro, Rosario ; De Giorgi, Ugo ; Schepisi, Giuseppe ; Basso, Umberto ; Bimbatti, Davide ; Rundo, Francesco ; Libra, Massimo ; Malatino, Lorenzo</creator><creatorcontrib>Banna, Giuseppe L. ; Urzia, Valeria ; Benanti, Chiara ; Pitrè, Alessandra ; Lipari, Helga ; Di Quattro, Rosario ; De Giorgi, Ugo ; Schepisi, Giuseppe ; Basso, Umberto ; Bimbatti, Davide ; Rundo, Francesco ; Libra, Massimo ; Malatino, Lorenzo</creatorcontrib><description>Purpose
To evaluate adherence to abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Methods
In an observational prospective cohort study, we monitored patients with mCRPC for their adherence to abiraterone or enzalutamide in the pre- or post-chemotherapy setting.
Results
Fifty-eight patients with median age of 76 years (range 56–94), age-adjusted Charlson comorbidity score of 10 (range, 4–15), and geriatric G8 score of 14 (range, 6–17) were enrolled. Twenty-two (38%) patients were treated with abiraterone and 36 (62%) with enzalutamide, while forty-two (72%) were in the pre-chemotherapy setting. Forty-seven patients (81%) had a caregiver. Based on the pill counting, a non-adherence rate of 4.8% and 6.2% was observed for the whole period and the first 3 months, respectively, without a statistically significant difference between abiraterone and enzalutamide cohorts. A lower non-adherence rate (1.3%) was reported by patients during the whole period, mainly due to a misperception (77%) and forgetfulness (19%). Non-adherence rate to the fulfilling of the clinical diary was 38% for the whole period. Non-adherence in the whole period was related to the radiological response (
p
= 0.03) and geriatric G8 score (
p
= 0.005). By the receiver operating characteristic (ROC) curve based on the radiological response, non-adherence cut-off was 1.87% (
p
= 0.04). By this non-adherence cut-off, the G8 cut-off was 14.75 (
p
= 0.0003).
Conclusion
Non-adherence to abiraterone or enzalutamide for mCRPC may have an impact on disease response and be related to patients’ frailty, suggesting their geriatric assessment and clinical interventions to monitor and increase their adherence.</description><identifier>ISSN: 0941-4355</identifier><identifier>EISSN: 1433-7339</identifier><identifier>DOI: 10.1007/s00520-020-05311-5</identifier><identifier>PMID: 31960124</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Aged, 80 and over ; Androstenes - administration & dosage ; Cancer ; Care and treatment ; Chemotherapy ; Cohort Studies ; Geriatrics ; Humans ; Male ; Medical screening ; Medication Adherence ; Medicine ; Medicine & Public Health ; Metastasis ; Middle Aged ; Neoplasm Metastasis ; Nursing ; Nursing Research ; Older people ; Oncology ; Oncology, Experimental ; Original Article ; Pain Medicine ; Patient compliance ; Phenylthiohydantoin - administration & dosage ; Phenylthiohydantoin - analogs & derivatives ; Prospective Studies ; Prostate cancer ; Prostatic Neoplasms, Castration-Resistant - drug therapy ; Prostatic Neoplasms, Castration-Resistant - pathology ; Rehabilitation Medicine ; Treatment Outcome</subject><ispartof>Supportive care in cancer, 2020-10, Vol.28 (10), p.4687-4695</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><rights>COPYRIGHT 2020 Springer</rights><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-d73748c89128aba7d7b8f0add7f97a4936d2f90e5fe83e4db72acd5c8927a0313</citedby><cites>FETCH-LOGICAL-c442t-d73748c89128aba7d7b8f0add7f97a4936d2f90e5fe83e4db72acd5c8927a0313</cites><orcidid>0000-0003-0764-3650</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00520-020-05311-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00520-020-05311-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31960124$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Banna, Giuseppe L.</creatorcontrib><creatorcontrib>Urzia, Valeria</creatorcontrib><creatorcontrib>Benanti, Chiara</creatorcontrib><creatorcontrib>Pitrè, Alessandra</creatorcontrib><creatorcontrib>Lipari, Helga</creatorcontrib><creatorcontrib>Di Quattro, Rosario</creatorcontrib><creatorcontrib>De Giorgi, Ugo</creatorcontrib><creatorcontrib>Schepisi, Giuseppe</creatorcontrib><creatorcontrib>Basso, Umberto</creatorcontrib><creatorcontrib>Bimbatti, Davide</creatorcontrib><creatorcontrib>Rundo, Francesco</creatorcontrib><creatorcontrib>Libra, Massimo</creatorcontrib><creatorcontrib>Malatino, Lorenzo</creatorcontrib><title>Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer</title><title>Supportive care in cancer</title><addtitle>Support Care Cancer</addtitle><addtitle>Support Care Cancer</addtitle><description>Purpose
To evaluate adherence to abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Methods
In an observational prospective cohort study, we monitored patients with mCRPC for their adherence to abiraterone or enzalutamide in the pre- or post-chemotherapy setting.
Results
Fifty-eight patients with median age of 76 years (range 56–94), age-adjusted Charlson comorbidity score of 10 (range, 4–15), and geriatric G8 score of 14 (range, 6–17) were enrolled. Twenty-two (38%) patients were treated with abiraterone and 36 (62%) with enzalutamide, while forty-two (72%) were in the pre-chemotherapy setting. Forty-seven patients (81%) had a caregiver. Based on the pill counting, a non-adherence rate of 4.8% and 6.2% was observed for the whole period and the first 3 months, respectively, without a statistically significant difference between abiraterone and enzalutamide cohorts. A lower non-adherence rate (1.3%) was reported by patients during the whole period, mainly due to a misperception (77%) and forgetfulness (19%). Non-adherence rate to the fulfilling of the clinical diary was 38% for the whole period. Non-adherence in the whole period was related to the radiological response (
p
= 0.03) and geriatric G8 score (
p
= 0.005). By the receiver operating characteristic (ROC) curve based on the radiological response, non-adherence cut-off was 1.87% (
p
= 0.04). By this non-adherence cut-off, the G8 cut-off was 14.75 (
p
= 0.0003).
Conclusion
Non-adherence to abiraterone or enzalutamide for mCRPC may have an impact on disease response and be related to patients’ frailty, suggesting their geriatric assessment and clinical interventions to monitor and increase their adherence.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Androstenes - administration & dosage</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Cohort Studies</subject><subject>Geriatrics</subject><subject>Humans</subject><subject>Male</subject><subject>Medical screening</subject><subject>Medication Adherence</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Nursing</subject><subject>Nursing Research</subject><subject>Older people</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Original Article</subject><subject>Pain Medicine</subject><subject>Patient compliance</subject><subject>Phenylthiohydantoin - administration & dosage</subject><subject>Phenylthiohydantoin - analogs & derivatives</subject><subject>Prospective Studies</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms, Castration-Resistant - drug therapy</subject><subject>Prostatic Neoplasms, Castration-Resistant - pathology</subject><subject>Rehabilitation Medicine</subject><subject>Treatment Outcome</subject><issn>0941-4355</issn><issn>1433-7339</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9Uc9vFiEQJUZjP6v_gAdD4sXLVmBgWY5fGn8lTbzombAwW2l22Qrsof71svmqjcYYMoHMvPeYmUfIS84uOGP6bWFMCdaxPRRw3qlH5MAlQKcBzGNyYEbyToJSZ-RZKTeMca2VeErOgJuecSEPxB_DN8yYPNK6UjfG7CrmNSFdM8X0w81bdUsMSGOiOAfM8x1dsLpSXY2e-vZolLimLmOJLZsqvc3rXsZWbcL5OXkyubngi_v7nHx9_-7L5cfu6vOHT5fHq85LKWoXNGg5-MFwMbjR6aDHYWIuBD0Z7aSBPojJMFQTDoAyjFo4H1QjCO0YcDgnb0667f_vG5Zql1g8zrNLuG7FCpDAFGfD0KCv_4LerFtOrTsrJPRG94qrB9S1m9HGNK1tVr-L2mMPoHqj5I66-AeqnYBL9G2VU2z5PwjiRPBtTyXjZG9zXFy-s5zZ3Vl7ctayPXZn7U56dd_xNi4YflN-WdkAcAKUVkrXmB9G-o_sT9oArd4</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Banna, Giuseppe L.</creator><creator>Urzia, Valeria</creator><creator>Benanti, Chiara</creator><creator>Pitrè, Alessandra</creator><creator>Lipari, Helga</creator><creator>Di Quattro, Rosario</creator><creator>De Giorgi, Ugo</creator><creator>Schepisi, Giuseppe</creator><creator>Basso, Umberto</creator><creator>Bimbatti, Davide</creator><creator>Rundo, Francesco</creator><creator>Libra, Massimo</creator><creator>Malatino, Lorenzo</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88J</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2R</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0764-3650</orcidid></search><sort><creationdate>20201001</creationdate><title>Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer</title><author>Banna, Giuseppe L. ; Urzia, Valeria ; Benanti, Chiara ; Pitrè, Alessandra ; Lipari, Helga ; Di Quattro, Rosario ; De Giorgi, Ugo ; Schepisi, Giuseppe ; Basso, Umberto ; Bimbatti, Davide ; Rundo, Francesco ; Libra, Massimo ; Malatino, Lorenzo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-d73748c89128aba7d7b8f0add7f97a4936d2f90e5fe83e4db72acd5c8927a0313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Androstenes - administration & dosage</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Cohort Studies</topic><topic>Geriatrics</topic><topic>Humans</topic><topic>Male</topic><topic>Medical screening</topic><topic>Medication Adherence</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Nursing</topic><topic>Nursing Research</topic><topic>Older people</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Original Article</topic><topic>Pain Medicine</topic><topic>Patient compliance</topic><topic>Phenylthiohydantoin - administration & dosage</topic><topic>Phenylthiohydantoin - analogs & derivatives</topic><topic>Prospective Studies</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms, Castration-Resistant - drug therapy</topic><topic>Prostatic Neoplasms, Castration-Resistant - pathology</topic><topic>Rehabilitation Medicine</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Banna, Giuseppe L.</creatorcontrib><creatorcontrib>Urzia, Valeria</creatorcontrib><creatorcontrib>Benanti, Chiara</creatorcontrib><creatorcontrib>Pitrè, Alessandra</creatorcontrib><creatorcontrib>Lipari, Helga</creatorcontrib><creatorcontrib>Di Quattro, Rosario</creatorcontrib><creatorcontrib>De Giorgi, Ugo</creatorcontrib><creatorcontrib>Schepisi, Giuseppe</creatorcontrib><creatorcontrib>Basso, Umberto</creatorcontrib><creatorcontrib>Bimbatti, Davide</creatorcontrib><creatorcontrib>Rundo, Francesco</creatorcontrib><creatorcontrib>Libra, Massimo</creatorcontrib><creatorcontrib>Malatino, Lorenzo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Sociology Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Supportive care in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Banna, Giuseppe L.</au><au>Urzia, Valeria</au><au>Benanti, Chiara</au><au>Pitrè, Alessandra</au><au>Lipari, Helga</au><au>Di Quattro, Rosario</au><au>De Giorgi, Ugo</au><au>Schepisi, Giuseppe</au><au>Basso, Umberto</au><au>Bimbatti, Davide</au><au>Rundo, Francesco</au><au>Libra, Massimo</au><au>Malatino, Lorenzo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer</atitle><jtitle>Supportive care in cancer</jtitle><stitle>Support Care Cancer</stitle><addtitle>Support Care Cancer</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>28</volume><issue>10</issue><spage>4687</spage><epage>4695</epage><pages>4687-4695</pages><issn>0941-4355</issn><eissn>1433-7339</eissn><abstract>Purpose
To evaluate adherence to abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Methods
In an observational prospective cohort study, we monitored patients with mCRPC for their adherence to abiraterone or enzalutamide in the pre- or post-chemotherapy setting.
Results
Fifty-eight patients with median age of 76 years (range 56–94), age-adjusted Charlson comorbidity score of 10 (range, 4–15), and geriatric G8 score of 14 (range, 6–17) were enrolled. Twenty-two (38%) patients were treated with abiraterone and 36 (62%) with enzalutamide, while forty-two (72%) were in the pre-chemotherapy setting. Forty-seven patients (81%) had a caregiver. Based on the pill counting, a non-adherence rate of 4.8% and 6.2% was observed for the whole period and the first 3 months, respectively, without a statistically significant difference between abiraterone and enzalutamide cohorts. A lower non-adherence rate (1.3%) was reported by patients during the whole period, mainly due to a misperception (77%) and forgetfulness (19%). Non-adherence rate to the fulfilling of the clinical diary was 38% for the whole period. Non-adherence in the whole period was related to the radiological response (
p
= 0.03) and geriatric G8 score (
p
= 0.005). By the receiver operating characteristic (ROC) curve based on the radiological response, non-adherence cut-off was 1.87% (
p
= 0.04). By this non-adherence cut-off, the G8 cut-off was 14.75 (
p
= 0.0003).
Conclusion
Non-adherence to abiraterone or enzalutamide for mCRPC may have an impact on disease response and be related to patients’ frailty, suggesting their geriatric assessment and clinical interventions to monitor and increase their adherence.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>31960124</pmid><doi>10.1007/s00520-020-05311-5</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-0764-3650</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-4355 |
| ispartof | Supportive care in cancer, 2020-10, Vol.28 (10), p.4687-4695 |
| issn | 0941-4355 1433-7339 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2343051088 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aged Aged, 80 and over Androstenes - administration & dosage Cancer Care and treatment Chemotherapy Cohort Studies Geriatrics Humans Male Medical screening Medication Adherence Medicine Medicine & Public Health Metastasis Middle Aged Neoplasm Metastasis Nursing Nursing Research Older people Oncology Oncology, Experimental Original Article Pain Medicine Patient compliance Phenylthiohydantoin - administration & dosage Phenylthiohydantoin - analogs & derivatives Prospective Studies Prostate cancer Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - pathology Rehabilitation Medicine Treatment Outcome |
| title | Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T16%3A21%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adherence%20to%20abiraterone%20or%20enzalutamide%20in%20elderly%20metastatic%20castration-resistant%20prostate%20cancer&rft.jtitle=Supportive%20care%20in%20cancer&rft.au=Banna,%20Giuseppe%20L.&rft.date=2020-10-01&rft.volume=28&rft.issue=10&rft.spage=4687&rft.epage=4695&rft.pages=4687-4695&rft.issn=0941-4355&rft.eissn=1433-7339&rft_id=info:doi/10.1007/s00520-020-05311-5&rft_dat=%3Cgale_proqu%3EA633569545%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2436976515&rft_id=info:pmid/31960124&rft_galeid=A633569545&rfr_iscdi=true |